DISEASE SCANNER
Global Incurable Diseases Tracker
Hodgkin Lymphoma
A lymphoid malignancy characterized by Reed-Sternberg cells in lymph nodes. Bimodal age distribution (young adults and elderly). Two main types: classical Hodgkin lymphoma (nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) and nodular lymphocyte-predominant.
300.0K
15
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Biopsy
- 2Imaging (CT, MRI, PET)
- 3Tumor markers
- 4Genetic testing
- 5Endoscopy
- 6Blood tests
- 7Screening programs
Prognosis
Early-stage disease has 90-95% cure rate with combined modality therapy. Advanced stage has 75-85% cure rate with chemotherapy. PET-adapted therapy improves outcomes. Relapsed/refractory disease has 50-60% salvage rate with high-dose chemotherapy + autologous stem cell transplant. Brentuximab vedotin and checkpoint inhibitors improve outcomes for transplant-ineligible or post-transplant relapse. Long-term survivors at risk for secondary cancers and cardiac disease.
Prevention
- Smoking cessation
- Sun protection
- Healthy diet
- Regular exercise
- Vaccination (HPV, HBV)
- Screening programs
- Limit alcohol
- Maintain healthy weight
Research Status
ABVD chemotherapy (doxorubicin, bleomycin, vinblastine, dacarbazine). PET-adapted therapy. Radiation for bulky disease. Nivolumab and pembrolizumab (PD-1 inhibitors) for relapsed/refractory. Brentuximab vedotin. Survival >85%.
Affected Countries
Sources
- https://www.cancer.gov
- https://www.who.int/cancer
- https://www.cancer.org
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.